Johnson & Johnson (NYSE:JNJ - Get Free Report) was upgraded by equities research analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating in a report released on Wednesday,Weiss Ratings reports.
JNJ has been the subject of a number of other reports. Barclays increased their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. UBS Group set a $198.00 target price on Johnson & Johnson in a research report on Friday, October 3rd. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Royal Bank Of Canada boosted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $189.88.
Get Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Price Performance
NYSE JNJ opened at $189.75 on Wednesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $456.98 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 2.41 and a beta of 0.40. The company has a 50 day moving average price of $177.49 and a two-hundred day moving average price of $163.37. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $190.22.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $27,000. Semmax Financial Advisors Inc. grew its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. GFG Capital LLC bought a new stake in Johnson & Johnson in the second quarter worth approximately $35,000. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Finally, Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the first quarter worth approximately $47,000. 69.55% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
